Abstract
Trastuzumab is a kind of monoclonal antibody widely used in cancer, especially in breast and stomach cancer. Due to the HER-2 expression in cardiomyocytes, it is most likely to affect normal cardiac function. Although combination therapies can reduce its toxicity to some extent, we still found toxicity in some combination therapies. In this review, we aim to summarize and analyze the toxicity found in combination therapy and give novel solutions to them. We have analyzed the combination toxicity including trastuzumab with ACE inhibitor, premedication, Emtansine, doxorubicin, and anthracycline taxane chemotherapy regimen. And we chose two main solutions as examples, including serum biomarkers and zingerone.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
